about
The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.Plant-Derived Anticancer Agents: Lessons from the Pharmacology of Geniposide and Its Aglycone, Genipin.MicroRNA-365 Inhibits Cell Growth and Promotes Apoptosis in Melanoma by Targeting BCL2 and Cyclin D1 (CCND1).Hypertension genomics and cardiovascular prevention
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
BCL2: A promising cancer therapeutic target.
@en
type
label
BCL2: A promising cancer therapeutic target.
@en
prefLabel
BCL2: A promising cancer therapeutic target.
@en
P1476
BCL2: A promising cancer therapeutic target.
@en
P2093
Gudapureddy Radha
Sathees C Raghavan
P304
P356
10.1016/J.BBCAN.2017.06.004
P407
P577
2017-06-21T00:00:00Z